www.swbio.com

Order: order@swbio.com Technical: tech@swbio.com



CLDN1

Catalog Number: 24240-1, 24240-2 **Amount:** 50μg/50μl, 100μg/100μl

Swiss-Prot No.: 095832

Form of Antibody: Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM

NaCl,0.02% sodium azide and 50% glycerol. Storage/Stability: Store at -20°C/1 year


Immunogen: The antiserum was produced against synthesized peptide derived from Human CLDN1 Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Specificity/Sensitivity: CLDN1 Antibody detects endogenous levels of total CLDN1

Reactivity: Human, Mouse, Rat

Applications:

Predicted MW:23kd WB:1:500-2000 IHC:1:50-200



Western blot analysis of extracts of various celllines, using CLDN1 antibody.

Background:

Tight junctions, or zonula occludens, form a continuous barrier to fluids across the epithelium and endothelium. They function in regulation of paracellular permeability and in the maintenance of cell polarity, blocking the movement of transmembrane proteins between the apical and the basolateral cell surfaces. Tight junctions are composed of claudin and occludin proteins, which join the junctions to the cytoskeleton. The claudin family is composed of 23 integral membrane proteins, and their expression, which varies among tissue types, may determine both the strength and properties of the epithelial barrier. Alteration in claudin protein expression pattern is associated with several types of cancer. Claudin-1 is expressed primarily in keratinocytes and normal mammary epithelial cells, but is absent or reduced in breast carcinomas and breast cancer cell lines .